Elias Jabbour, David Sallman, Debbie Briseno-Toomey, Christina Drenberg Guttke, Xiaojun Huang, Richard Dillon, Lucille Ferrante, Takayuki Ikezoe, Angélique Langlois, Christina Loefgren, Boaz Nachmias, Ayelet Nelson, Kathryn Packman, Prathap Nagaraja Shastri, Christian Récher, Gail Roboz, Natasha Schuier, Meena Thayu, Danielle Trancucci, Athena Zuppa, Christoph Röllig, Andrew Wei. "Camelot-2: A phase 3 randomized, double-blind, placebo-controlled, study of bleximenib, venetoclax and azacitidine for the treatment of participants with newly diagnosed Acute Myeloid Leukemia harboring KMT2A rearrangements or NPM1 mutations, who are ineligible for intensive chemotherapy." Blood, 2025. doi:10.1182/blood-2025-3429